Tegaserod til behandling af kvinder med colon irritabile

Lars Kristian Munck*, Mark Andrew Ainsworth

*Corresponding author af dette arbejde

    Publikation: Bidrag til tidsskriftReviewForskningpeer review


    Irritable bowel syndrome (IBS) is a chronic, relapsing disease characterised by abdominal pain and altered bowel movements. This review assesses the clinical trials of the partial serotonin receptor agonist tegaserod in women with constipation type IBS. Significantly more women treated with tegaserod obtained sufficient relief from symptoms during at least 2 out of 4 weeks, but the absolute therapeutic gain of approximately 10 percent was not deemed clinically relevant. Two marketing authorisation applications in the European Union have been rejected due to the minor therapeutic gain. Tegaserod was removed from the market in the USA in March 2007 due to an increased risk of severe cardiovascular adverse events.

    Bidragets oversatte titelTegaserod in treatment of women with irritable bowel syndrome
    Sider (fra-til)2190-2192
    Antal sider3
    TidsskriftUgeskrift for laeger
    Udgave nummer23
    StatusUdgivet - 4 jun. 2007


    Udforsk hvilke forskningsemner 'Tegaserod til behandling af kvinder med colon irritabile' indeholder.